Avicena LVDP Validation Study in Healthy Volunteers
Launched by AVICENA LLC · Dec 21, 2022
Trial Information
Current as of June 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult subjects \>21 years of age.
- • 2. No known significant health problems.
- • 3. Willing and able to participate in all study evaluations.
- • 4. Ability to understand and sign informed consent.
- Exclusion Criteria:
- • 1. Open skin lesions at the site of Vivio application / examination.
- • 2. Inability to obtain brachial artery blood pressure.
About Avicena Llc
Avicena LLC is a biopharmaceutical company dedicated to advancing innovative therapeutic solutions for neurological and psychiatric disorders. With a strong focus on research and development, Avicena leverages cutting-edge science and technology to create novel treatments aimed at improving patient outcomes. Their commitment to clinical excellence is reflected in rigorous trial designs and partnerships with leading research institutions, ensuring that their therapies are both safe and effective. Avicena LLC strives to make a meaningful impact in the lives of individuals affected by complex neurological conditions through rigorous scientific inquiry and a patient-centered approach.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pasadena, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials